No immediate financial impact is indicated. Traders should monitor future Form 4 filings for any actual purchases or sales by these insiders, which could signal confidence or concern.
Price Chart
Executive Summary
Two Form 3 filings were submitted for First Tracks Biotherapeutics, Inc. (TRAX) on April 1, 2026, disclosing initial beneficial ownership by Paul F. Lizzul, the company's Chief Medical Officer, and John A. Orwin, a director. These are routine initial ownership reports following appointments or share grants, with no financial details disclosed about the holdings.
Key Facts
- Paul F. Lizzul, Chief Medical Officer, filed Form 3 disclosing initial beneficial ownership as of April 1, 2026.
- John A. Orwin, director, filed Form 3 disclosing initial beneficial ownership as of April 1, 2026.
- No specific number of shares or dollar value was disclosed in the filings.
- Both filings are standard regulatory requirements under Section 16(a) for insiders upon assuming their roles.
Financial Impact
undisclosed amount
Risk Factors
- Lack of disclosed share amounts limits insight into insider commitment or dilution impact.
- No financial data in Form 3 filings means no direct market-moving information is available.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (TRAX) — Batch item 1 | 0001711462-26-000008 |
| Document: 0001711462-26-000008-index.html | 0001477384-26-000003 |
| Document: 0001711462-26-000008.txt | 0001711462-26-000008 |
| 3 Filing (TRAX) — Batch item 4 | 0001477384-26-000003 |
| Document: 0001477384-26-000003-index.html | 0001711462-26-000008 |
| Document: 0001477384-26-000003.txt | 0001711462-26-000008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers